| 12.61 0.12 (0.96%) | 10-08 15:15 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 15.49 | 1-year : | 18.1 |
| Resists | First : | 13.27 | Second : | 15.49 |
| Pivot price | 12.56 |
|||
| Supports | First : | 11.97 | Second : | 11.18 |
| MAs | MA(5) : | 12.44 |
MA(20) : | 12.5 |
| MA(100) : | 10.34 |
MA(250) : | 9.87 |
|
| MACD | MACD : | 0.2  |
Signal : | 0.3 |
| %K %D | K(14,3) : | 44.1 |
D(3) : | 36.4 |
| RSI | RSI(14): 59.7 |
|||
| 52-week | High : | 13.27 | Low : | 6.21 |
Price has closed above its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is BULLISH in short-term; and BULLISH in mid-long term.[ ZYME ] has closed below upper band by 45.6%. Bollinger Bands are 35.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 12.63 - 12.69 | 12.69 - 12.74 |
| Low: | 12.21 - 12.29 | 12.29 - 12.36 |
| Close: | 12.37 - 12.5 | 12.5 - 12.6 |
Zymeworks Inc., a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a novel bispecific antibody that is in Phase 1 and Phase 2 clinical trials for the treatment of biliary tract, gastroesophageal adenocarcinomas, breast, and colorectal cancer; and ZW49, a biparatopic anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate that is in Phase 1 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors. The company has strategic partnerships with Merck Sharp & Dohme Research Ltd.; Eli Lilly and Company; Bristol-Myers Squibb company; GlaxoSmithKline Intellectual Property Development Ltd.; Daiichi Sankyo Co., Ltd.; Janssen Biotech, Inc.; BeiGene, Ltd.; and Exelixis, Inc. It also has licensing and research collaboration with LEO Pharma A/S to research, develop, and commercialize bispecific antibodies; and Iconic Therapeutics, Inc. Zymeworks Inc. was incorporated in 2003 and is headquartered in Vancouver, Canada.
Mon, 07 Oct 2024
Healthcare of Ontario Pension Plan Trust Fund Reduces Holdings in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Thu, 03 Oct 2024
Renaissance Technologies LLC Increases Stock Position in Zymeworks Inc. (NYSE:ZYME) - MarketBeat
Fri, 27 Sep 2024
Zymeworks Approaching A Moment Of Truth With Zanidatamab (NASDAQ:ZYME) - Seeking Alpha
Tue, 03 Sep 2024
Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c) - GlobeNewswire
Thu, 22 Aug 2024
Zymeworks Engages Investors, Awaits Drug Approval - TipRanks
Wed, 07 Aug 2024
Analysts Are Betting On Zymeworks Inc. (NASDAQ:ZYME) With A Big Upgrade This Week - Simply Wall St
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Underperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NYSE
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 71 (M) |
| Shares Float | 43 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 98.5 (%) |
| Shares Short | 3,700 (K) |
| Shares Short P.Month | 3,730 (K) |
| EPS | -1.5 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 5.73 |
| Profit Margin | -179.5 % |
| Operating Margin | -133.1 % |
| Return on Assets (ttm) | -13.7 % |
| Return on Equity (ttm) | -26.4 % |
| Qtrly Rev. Growth | 174.8 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0.88 |
| EBITDA (p.s.) | -1.63 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -91 (M) |
| Levered Free Cash Flow | -64 (M) |
| PE Ratio | -8.41 |
| PEG Ratio | -1 |
| Price to Book value | 2.19 |
| Price to Sales | 14.28 |
| Price to Cash Flow | -9.81 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|